7.94
전일 마감가:
$6.895
열려 있는:
$7
하루 거래량:
211.76K
Relative Volume:
3.80
시가총액:
$29.22M
수익:
-
순이익/손실:
$-31.11M
주가수익비율:
-5.1895
EPS:
-1.53
순현금흐름:
$-28.18M
1주 성능:
+29.53%
1개월 성능:
+15.91%
6개월 성능:
-30.36%
1년 성능:
-82.09%
Tempest Therapeutics Inc Stock (TPST) Company Profile
명칭
Tempest Therapeutics Inc
전화
415-798-8589
주소
2000 SIERRA POINT PARKWAY, BRISBANE
TPST을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
TPST
Tempest Therapeutics Inc
|
7.94 | 22.57M | 0 | -31.11M | -28.18M | -1.53 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Tempest Therapeutics Inc Stock (TPST) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-04-10 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2025-04-10 | 다운그레이드 | Scotiabank | Sector Outperform → Sector Perform |
2024-03-14 | 개시 | Scotiabank | Sector Outperform |
2024-02-08 | 개시 | Jefferies | Buy |
Tempest Therapeutics Inc 주식(TPST)의 최신 뉴스
Tempest Therapeutics stock rises on EMA Orphan Drug Designation - Investing.com
Tempest Therapeutics Says Amezalpat Gets EMA Orphan Drug Designation in Liver Cancer - marketscreener.com
Tempest Therapeutics: European Medicines Agency Grants Orphan Drug Designation To Amezalpat - Nasdaq
TPST Receives EMA Orphan Drug Designation for Liver Cancer Treatment | TPST Stock News - GuruFocus
Tempest Receives Orphan Drug Designation from the European - GlobeNewswire
Tempest Therapeutics Reports Q1 2025 Financial Results - TipRanks
HC Wainwright Issues Optimistic Estimate for TPST Earnings - Defense World
Tempest Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Layoff Tracker: Allogene Cuts 28% of Staff to Extend Runway, Focus on Clinical Programs - BioSpace
TPST Highlights Promising Data for Cancer Therapy | TPST Stock N - GuruFocus
Tempest Therapeutics Q1 Operating Income USD -10.936 Million - marketscreener.com
Tempest Therapeutics Reports Positive Amezalpat Data and FDA Designations for Cancer Treatment Programs - Nasdaq
Tempest Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
FDA Grants Multiple Key Designations to Tempest Cancer Drugs as New AACR Data Shows Promise - Stock Titan
Millendo Therapeutics, Inc. Announces Board Changes - marketscreener.com
Cash-strapped Bay Area biotech company lays off all but 5 employees - MSN
Tempest Therapeutics Inc expected to post a loss of $3.29 a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $296,000 Stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
XTX Topco Ltd Has $134,000 Position in Tempest Therapeutics, Inc. (NASDAQ:TPST) - Defense World
Tempest Therapeutics regains Nasdaq compliance By Investing.com - Investing.com Canada
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting - The Manila Times
Tempest Therapeutics Presents Promising Amezalpat Data at 2025 AACR Annual Meeting, Supporting Novel Cancer Treatment Mechanism - Nasdaq
Tempest Presents New Amezalpat MOA Data Reinforcing Its - GlobeNewswire
Breakthrough: New Cancer Drug Amezalpat Demonstrates Dual Anti-Cancer Mechanism in Multiple Tumors - Stock Titan
Tempest Therapeutics regains Nasdaq compliance - Investing.com
Market Recap Check: Tempest Therapeutics Inc (TPST)’s Negative Finish at 0.61, Up/Down -14.53 - DWinneX
Struggling Bay Area biotech company, once worth $1B, lays off all but 5 workers - SFGATE
Tempest Therapeutics - The Pharma Letter
Tempest Therapeutics stock rises on FDA Orphan Drug Designation By Investing.com - Investing.com Nigeria
Tempest Therapeutics stock rises on FDA Orphan Drug Designation - Investing.com Australia
Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP - The Manila Times
FDA Awards Rare Disease Drug Status to Tempest's Novel FAP Treatment: Phase 2 Trial Coming in 2025 - Stock Titan
Tempest to explore alternatives to advance promising pipeline - The Pharma Letter
TPST to Evaluate Strategic Options for Pipeline Studies, Stock Up - MSN
Scotiabank Reaffirms “Sector Perform” Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
HC Wainwright Reaffirms Neutral Rating for Tempest Therapeutics (NASDAQ:TPST) - Defense World
Tempest Therapeutics Retail Chatter Explodes As Cancer Drug Developer Mulls Possible Merger - Asianet Newsable
Tempest Weighs M&A, Analyst Sees A "Broken Story" Despite Phase 2 Liver Cancer Study Success - Benzinga
Tempest seeks strategic alternatives as cash runs out for Phase 3 trial - BioPharma Dive
HC Wainwright Downgrades Tempest Therapeutics to Neutral From Buy - marketscreener.com
Tempest hits funding block for Phase III liver cancer drug-in-waiting - Yahoo Finance
Tempest seeks strategic alternatives to fund Phase 3 liver cancer trial - Endpoints News
Tempest Therapeutics evaluates strategic options amid advancements By Investing.com - Investing.com South Africa
Tempest Therapeutics Terminates Loan Agreement with Oxford - TipRanks
Tempest Therapeutics Seeks Partner as It Explores Strategic Alternatives - marketscreener.com
Tempest Therapeutics Mulls Alternatives to Advance Cancer Treatment Programs - marketscreener.com
Tempest Therapeutics Inc (TPST) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):